Helix BioPharma Announces Director Resignation

(firmenpresse) - AURORA, ON -- (Marketwire) -- 02/10/13 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announced that on Friday, February 8, 2013 John A. Rogers has voluntarily resigned from Helix's board of directors.



Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP."



Helix BioPharma Corp.
Tel: 905 841-2300
Email:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 10.02.2013 - 16:01 Uhr
Sprache: Deutsch
News-ID 227912
Anzahl Zeichen: 0

contact information:
Town:

AURORA, ON

Kategorie:

Biotech

Diese Pressemitteilung wurde bisher 281 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Helix BioPharma Announces Director Resignation"
steht unter der journalistisch-redaktionellen Verantwortung von

Helix BioPharma Corp. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Helix BioPharma Corp. Announces Fiscal 2017 Year-End Results and Provides Resear ...

RICHMOND HILL, ONTARIO -- (Marketwired) -- 10/27/17 -- Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the ...

Helix BioPharma Corp. Closes Private Placement ...

RICHMOND HILL, ONTARIO -- (Marketwired) -- 10/19/17 -- Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatmen ...

Helix BioPharma Corp. announces FDA approval to Accelerate Dose Escalation for U ...

RICHMOND HILL, ONTARIO -- (Marketwired) -- 09/27/17 -- Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the preventio ...

Alle Meldungen von Helix BioPharma Corp.